glp 1 nafld Full article: GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients Resolution of NASH and hepatic

At the same time, it inhibits the release of glucagon into the bloodstream and slows down the rate at which food leaves your stomach

The SURMOUNT trials demonstrated tirzepatide at 15 mg achieving 15% to 21% body weight loss by week 72, about 17 months

GLP-1 medications have been shown to have many benefits in treating obesity and type 2 diabetes

While the trials were negative clinically, presenters and discussants noted biomarker changes consistent with reduced neuroinflammation (e.g., decreases in highsensitivity CRP) and other Alzheimersrelated signalsmodest but statistically significant effects that did not yield measurable cognitive benefit

JENNIFER COUZIN-FRANKEL (08-09-2023)